| Literature DB >> 20826490 |
Sebastiano Mercadante1, Patrizia Ferrera, Fabrizio David, Alessandra Casuccio.
Abstract
A retrospective study of patients who were prescribed controlled-release oxycodone (CRO) in a period of 3 years (2006-2008) was performed. A total of 212 patients were prescribed at discharge CRO for background analgesia; 129, 43, and 40 patients were prescribed doses of oxycodone of less than 120 mg/day (group L), 120 to 240 mg/day (group M), and more than 240 mg/day (group L), respectively. No differences in gender, primary diagnosis, and pain mechanisms were found, but doses were significantly lower in older patients (P < .0005). At discharge, adverse effects were mild and only a minority of patients were switched to other opioids. This study demonstrated that CRO administered in larger doses was safe and effective, showing versatility and flexibility similar to morphine.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20826490 DOI: 10.1177/1049909110381378
Source DB: PubMed Journal: Am J Hosp Palliat Care ISSN: 1049-9091 Impact factor: 2.500